Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program.

@article{Butner2017OnsiteTO,
  title={Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program.},
  author={Jenna L Butner and Neil Gupta and Chris Fabian and Susan Henry and Julia M Shi and Jeanette M. Tetrault},
  journal={Journal of substance abuse treatment},
  year={2017},
  volume={75},
  pages={
          49-53
        }
}
With the advent of the direct acting antivirals (DAA), or all oral HCV treatment regimens, there exists a great opportunity to provide HCV treatment to people who inject drugs (PWID) enrolled in an opioid treatment program (OTP). This retrospective study conducted in the context of routine clinical care explores the outcomes of HCV treatment with DAAs in PWID enrolled in an OTP. Our study showed treatment outcomes among our first 75 patients treated with DAAs were nearly equivalent to patients… CONTINUE READING

Tables and Topics from this paper.

Explore Further: Topics Discussed in This Paper

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Limited Uptake of Hepatitis C Treatment Among Injection Drug Users

Shruti H. Mehta, Becky L. Genberg, +5 authors David L. Thomas
  • Journal of Community Health
  • 2007
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Emerging biological agents for hepatitis C.

  • Expert opinion on emerging drugs
  • 2016
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy

G. Dore, A F., Litwin, H A.
  • 2015
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Global policy and access to new hepatitis C therapies for people who inject drugs.

  • The International journal on drug policy
  • 2015
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

HCV guidance: Recommendations for testing, managing, and treating hepatitis C

AASLD
  • Retrieved from http://hcvguidelines.org/
  • 2016
VIEW 3 EXCERPTS